Ikena Oncology
Updated: December 31, 2025
Mark Manfredi - President and CEO
Country: USA | Funding: $209M (+)
Founded: 2016
Website: https://ikenaoncology.com/
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
Founded: 2016
Website: https://ikenaoncology.com/
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
